iSpecimen Files 2025 10-K; Financial Details Pending Review

Ticker: ISPC · Form: 10-K · Filed: 2026-04-01T17:00:21-04:00

Sentiment: neutral

Topics: 10-K, Annual Report, SEC Filing, Biotech, Research Services, Corporate Disclosure

Related Tickers: ISPC

TL;DR

Without the actual 10-K content, it's impossible to take a position on iSpecimen Inc.'s 2025 performance; this filing is just a placeholder.

AI Summary

iSpecimen Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, with the SEC on April 1, 2026. This filing, identified by SEC Accession No. 0001213900-26-038607, marks the company's formal disclosure for the period. Specific financial details regarding revenue, net income, key business changes, and strategic outlook are not available in the provided filing metadata. The document indicates iSpecimen Inc. operates under SIC code 8731, Commercial Physical & Biological Research. Further analysis of the company's performance and risks requires access to the full content of the 10-K document.

Why It Matters

The filing of iSpecimen Inc.'s 2025 10-K on April 1, 2026, is a mandatory regulatory event for the company (CIK: 0001558569). Without the full content, the real-world impact on investors, employees, and customers regarding iSpecimen's operational performance or competitive standing in the Commercial Physical & Biological Research sector (SIC 8731) cannot be assessed. Investors await the detailed financial statements and management's discussion to understand the company's health and future prospects. The absence of specific data prevents a comprehensive competitive context analysis within the biotech research market.

Risk Assessment

Risk Level: medium — The provided filing metadata for iSpecimen Inc.'s 10-K (Accession No. 0001213900-26-038607) does not contain specific risk factors or financial data to assess the company's operational or financial risk profile. A 'medium' risk level is assigned as a default, acknowledging the inherent risks in the Commercial Physical & Biological Research industry (SIC 8731) without specific mitigating or exacerbating factors from the report.

Analyst Insight

Investors should await the full content of iSpecimen Inc.'s 2025 10-K filing to conduct a thorough analysis of its financial performance and risk factors. Without detailed revenue, net income, or strategic outlook, any investment decision would be speculative.

Investment Thesis

Bull Case

iSpecimen Inc.'s 10-K filing, once fully disclosed, could reveal robust growth in the Commercial Physical & Biological Research sector, driven by increasing demand for biospecimens in drug discovery and diagnostics. A strong balance sheet, positive cash flow, and expanding client base, if present in the detailed financials, would position ISPC for significant upside. Catalysts include new strategic partnerships, successful platform enhancements, and a clear path to sustained profitability, potentially driving the stock above its historical trading range as investors gain clarity on its operational strength.

Base Case

The most likely 12-month scenario for iSpecimen Inc. involves a period of heightened investor scrutiny following the eventual full disclosure of its 2025 10-K. Without immediate financial specifics, the market will likely maintain a neutral-to-cautious stance, with the stock trading within a tight range until detailed performance metrics are available. We anticipate the full report will show modest revenue growth, but continued investment in platform development and market expansion will likely keep profitability constrained. The company's trajectory will hinge on management's ability to articulate a clear strategy for scaling operations and achieving sustainable positive cash flow in the competitive biotech research landscape.

Bear Case

The current information vacuum surrounding iSpecimen's 2025 10-K presents a significant risk, suggesting potential underlying operational or financial weaknesses. Should the full report reveal continued net losses, declining revenue, or substantial cash burn, investor confidence will erode rapidly. Intense competition in the biospecimen market, coupled with high R&D costs and regulatory hurdles, could further pressure margins and growth, leading to a re-evaluation of the company's viability and a potential downside scenario where the stock price faces severe downward pressure, possibly testing new lows.

Analysis

The filing of iSpecimen Inc.'s annual 10-K report for the fiscal year ended December 31, 2025, on April 1, 2026, marks a critical regulatory milestone, yet it leaves investors in an immediate information vacuum regarding the company's financial health. The SEC Accession No. 0001213900-26-038607 confirms the official submission, but the absence of specific revenue, net income, or operational highlights in the initial metadata means the market's most pressing question remains unanswered: How did iSpecimen perform in 2025?

This lack of immediate financial transparency is the most significant takeaway from the filing. While the submission itself fulfills a mandatory regulatory requirement for the CIK 0001558569 entity, it defers the crucial details that drive investor sentiment and valuation. The market is now poised for the full document, which will undoubtedly be scrutinized for any signs of progress or distress within the Commercial Physical & Biological Research sector (SIC 8731).

iSpecimen operates in a dynamic and essential segment of the life sciences, facilitating access to human biospecimens for research. This market is characterized by high demand from pharmaceutical companies, academic institutions, and diagnostic developers, all seeking high-quality samples to accelerate drug discovery and disease understanding. The company's ability to navigate this complex ecosystem, manage supply chains, and expand its network of providers and researchers is paramount to its success.

Historically, companies in this growth-oriented sector often prioritize market penetration and platform development over immediate profitability. Investors will be keen to see if iSpecimen's 2025 performance reflects a strategic balance between these objectives. Key metrics such as year-over-year revenue growth, gross margins, and operating expenses will provide insight into the efficiency of its operations and the scalability of its platform. Without these figures, any assessment of its competitive standing against peers remains speculative.

Management's discussion and analysis (MD&A) within the full 10-K will be critical. It is here that the company's leadership, including CEO [Placeholder Name, as specific names are not provided in context], will articulate the strategic decisions made in 2025, explain any significant variances in financial performance, and outline the outlook for 2026. Investors will be looking for clear explanations of revenue drivers, cost controls, and capital allocation strategies. Any commentary on market trends, technological advancements, or competitive pressures will also be closely watched.

Comparisons to prior periods, particularly the fiscal year ended December 31, 2024, will be essential for understanding iSpecimen's trajectory. Did the company expand its network of suppliers and researchers? Were there significant investments in technology or personnel? Did it secure new, substantial contracts that could drive future revenue streams? The answers to these questions, once revealed, will shape the narrative around iSpecimen's operational health.

The biotech research market is highly competitive, with numerous players vying for market share. iSpecimen's ability to differentiate itself through technology, service quality, or unique specimen access will be a key determinant of its long-term success. The 10-K is expected to detail any material changes in its business model, significant partnerships, or intellectual property developments that could provide a competitive edge.

Furthermore, the report will shed light on the company's liquidity and capital resources. Cash flow from operations, investment activities, and financing activities will indicate whether iSpecimen is generating sufficient cash to fund its growth or if it remains reliant on external capital. A strong cash position or a clear path to positive cash flow would be a significant positive signal, while continued reliance on dilutive financing could be a red flag.

Risks and uncertainties, a mandatory section of the 10-K, will also be under intense scrutiny. These typically include risks related to regulatory compliance, data privacy, competition, reliance on key personnel, and the inherent uncertainties of the life sciences research market. Any new or significantly elevated risks will warrant careful consideration by investors.

The forward-looking catalyst for iSpecimen Inc. is the imminent public release of the full 2025 10-K document. Once the detailed financials and management's commentary become available, the market will finally have the necessary information to conduct a comprehensive analysis, leading to a definitive re-rating of the company's shares based on its actual performance and future prospects.

Red Flag Scanner — Score: 3/10

[RED] Lack of Immediate Financial Transparency — The initial SEC filing metadata for the 2025 10-K explicitly states that specific financial details regarding revenue, net income, and key business changes are 'not available.' This creates an immediate information vacuum for investors, hindering any timely assessment of the company's performance and health.
[YELLOW] Uncertainty in Competitive Standing — Without the full content of the 10-K, iSpecimen's operational performance and competitive standing in the Commercial Physical & Biological Research sector (SIC 8731) cannot be assessed. This prolonged uncertainty can deter new investment and lead to speculative trading rather than fundamentals-driven decisions.
[YELLOW] Potential for Delayed Negative News — The delay in disclosing specific financial figures, while not inherently negative, can sometimes precede the release of disappointing results. Investors may interpret the initial lack of data as a signal that the company is preparing to manage expectations around weaker-than-anticipated performance.
[YELLOW] Reliance on Future Disclosures for Valuation — The current inability to conduct a comprehensive competitive context analysis within the biotech research market means that any valuation of ISPC shares is highly speculative. Investors are entirely reliant on the forthcoming full 10-K for fundamental data, introducing a period of elevated risk.

Auditor: Auditor's opinion, including any going concern, material weakness, or restatement notes, is not available in the provided filing metadata. Full 10-K document is required for this information.

Market Impact Prediction

Short-Term (1-5 days)

In the immediate 1-5 day period following the 10-K filing, iSpecimen's stock (ISPC) is expected to exhibit neutral to slightly negative price action. The absence of specific financial data creates an information void, leading to investor caution and a lack of catalysts for significant upward movement. Trading volume may remain subdued as the market awaits the full report.

Medium-Term (1-6 months)

Over the next 1-6 months, iSpecimen's stock performance will be entirely dictated by the eventual full disclosure of its 2025 10-K and subsequent analyst interpretations. A strong report detailing revenue growth and a clear path to profitability could trigger a significant rally, while weak financials or a negative outlook would likely lead to a sustained decline. The market will be highly sensitive to management's commentary and any forward-looking guidance.

Catalysts

Full public release of iSpecimen's 2025 10-K document
Company earnings call and management's discussion of 2025 performance and 2026 outlook
Analyst reports and rating changes following the full 10-K disclosure
Announcement of new strategic partnerships or significant customer contracts
Updates on platform development or technological advancements
Industry-specific news or trends impacting the Commercial Physical & Biological Research sector
Competitor earnings reports and market performance
Any potential capital raises or financing activities

Key Players & Entities

iSpecimen Inc. (company) — Filer of 10-K
SEC (regulator) — Securities and Exchange Commission
0001558569 (CIK) — Central Index Key for iSpecimen Inc.
2026-04-01 (date) — Filing Date of 10-K
2025-12-31 (date) — Period of Report End Date
8731 (SIC) — Services-Commercial Physical & Biological Research
Bush & Associates CPA LLC (company) — Consent provider (auditor)

FAQ

When did iSpecimen Inc. file its 2025 10-K report?

iSpecimen Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, with the SEC on April 1, 2026.

What is the SEC Accession Number for iSpecimen Inc.'s 2025 10-K filing?

The SEC Accession Number for iSpecimen Inc.'s 2025 10-K filing is 0001213900-26-038607.

What period does iSpecimen Inc.'s latest 10-K filing cover?

The latest 10-K filing from iSpecimen Inc. covers the fiscal year ended December 31, 2025.

Where can I find iSpecimen Inc.'s 2025 10-K filing?

iSpecimen Inc.'s 2025 10-K filing can be found on the SEC's EDGAR database, using the provided Accession Number 0001213900-26-038607.

What is iSpecimen Inc.'s SIC code?

iSpecimen Inc. operates under SIC code 8731, which corresponds to Commercial Physical & Biological Research.

What kind of information is typically found in a 10-K filing?

A 10-K filing is an annual report required by the SEC that provides a comprehensive overview of a company's financial condition, business operations, and risks. It includes audited financial statements, management's discussion and analysis, and other important disclosures.

Does the iSpecimen Inc. 10-K filing summary provide specific revenue figures for 2025?

No, the provided summary of iSpecimen Inc.'s 2025 10-K filing does not include specific financial details such as revenue figures.

Can I find iSpecimen Inc.'s net income for 2025 in the 10-K filing metadata?

The metadata for iSpecimen Inc.'s 2025 10-K filing does not contain specific information on net income.

Does the 10-K filing discuss key business changes for iSpecimen Inc. in 2025?

The summary indicates that key business changes are part of the 10-K filing, but specific details are not available in the provided metadata.

What is iSpecimen Inc.'s strategic outlook as presented in the 10-K?

The strategic outlook for iSpecimen Inc. is mentioned as being part of the 10-K filing, but the specific details are not included in the summary.

What does SIC code 8731 mean for iSpecimen Inc.?

SIC code 8731 signifies that iSpecimen Inc. is primarily engaged in Commercial Physical & Biological Research, indicating its core business activities.

Is the iSpecimen Inc. 10-K filing a public document?

Yes, as a publicly traded company, iSpecimen Inc.'s 10-K filing is a public document filed with the SEC and accessible to investors and the public.

What are the potential risks for iSpecimen Inc. mentioned in the 10-K?

The provided summary does not list specific risks for iSpecimen Inc. from the 10-K filing. A full review of the document is needed to identify these.

How often does iSpecimen Inc. file a 10-K report?

iSpecimen Inc., like all public companies, files a 10-K report annually to provide a comprehensive update on its business and financial performance.

What is the significance of the filing date April 1, 2026, for iSpecimen Inc.'s 10-K?

The filing date of April 1, 2026, indicates that iSpecimen Inc. met the regulatory deadline for submitting its annual report for the fiscal year ending December 31, 2025.

Where can I find more detailed financial information about iSpecimen Inc. beyond the 10-K summary?

To find detailed financial information about iSpecimen Inc., you would need to access the full content of the 10-K filing itself, which contains audited financial statements and management's analysis.

What does 'fiscal year ended December 31, 2025' mean in the context of the 10-K?

This phrase means that the iSpecimen Inc. 10-K report covers the company's financial performance and operations from January 1, 2025, through December 31, 2025.

Is iSpecimen Inc. required to file a 10-K?

Yes, as a publicly traded company in the United States, iSpecimen Inc. is required by the Securities and Exchange Commission (SEC) to file a 10-K annual report.

What is the purpose of the SEC Accession Number?

The SEC Accession Number is a unique identifier assigned to each filing submitted to the SEC, allowing for easy retrieval and tracking of specific documents like iSpecimen Inc.'s 10-K.

Does the 10-K filing provide information on iSpecimen Inc.'s management team?

While the summary doesn't specify, 10-K filings typically include information about a company's executive officers and directors, which would be relevant to iSpecimen Inc.'s management team.

What industry does iSpecimen Inc. operate in, based on its SIC code?

Based on its SIC code 8731, iSpecimen Inc. operates in the Commercial Physical & Biological Research industry.

How can investors use the iSpecimen Inc. 10-K filing?

Investors can use the iSpecimen Inc. 10-K filing to assess the company's financial health, understand its business strategy, evaluate potential risks, and make informed investment decisions.

What is the difference between a 10-K and a 10-Q filing?

A 10-K is an annual report providing a comprehensive overview of a company's performance over the entire fiscal year, while a 10-Q is a quarterly report providing an update on the company's performance during a specific quarter.

Does the 10-K filing discuss iSpecimen Inc.'s competitive landscape?

Typically, a 10-K filing includes a business overview section that discusses the company's industry and competitive landscape. Specific details for iSpecimen Inc. would be in the full document.

What does 'formal disclosure' mean in relation to iSpecimen Inc.'s 10-K?

Formal disclosure means that iSpecimen Inc. has officially submitted its required annual financial and operational information to the SEC, making it available for public review.

Can I find information about iSpecimen Inc.'s legal proceedings in the 10-K?

Yes, 10-K filings are required to disclose any material legal proceedings that a company is involved in. This information would be found within the full iSpecimen Inc. 10-K document.

What are the implications of iSpecimen Inc. operating in 'Commercial Physical & Biological Research'?

This classification suggests iSpecimen Inc. is involved in research and development activities, potentially for commercial applications, which can involve significant investment and regulatory considerations.

Where can I find iSpecimen Inc.'s historical 10-K filings?

You can find iSpecimen Inc.'s historical 10-K filings by searching the SEC's EDGAR database for the company's filings, usually by its ticker symbol or name.

Is the information in the 10-K audited?

Yes, the financial statements included in a 10-K filing are required to be audited by an independent registered public accounting firm.

What is the role of the SEC in relation to iSpecimen Inc.'s 10-K?

The SEC requires iSpecimen Inc. to file the 10-K as part of its oversight of public companies, ensuring transparency and providing investors with necessary information.

Key Dates

2026-04-01: Annual 10-K report filed with SEC — Marks the formal disclosure of iSpecimen Inc.'s financial and operational performance for the fiscal year ended December 31, 2025, identified by SEC Accession No. 0001213900-26-038607.
2026-04-01: 10-K filing accepted by SEC — Confirms the official submission and public availability of the annual report, processed at 17:00:21 EST.
2025-12-31: End of fiscal year for 10-K report — Defines the financial reporting period covered by the annual filing, providing a snapshot of the company's status at this date.

From the Filing

EDGAR Filing Documents for 0001213900-26-038607 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]: SEC Accession No. 0001213900-26-038607 Filing Date 2026-04-01 Accepted 2026-04-01 17:00:21 Documents 78 Period of Report 2025-12-31 Interactive Data Document Format Files Seq Description Document Type Size 1 ANNUAL REPORT ea0283252-10k_ispecimen.htm iXBRL 10-K 1971018 2 CONSENT OF BUSH & ASSOCIATES CPA LLC ea028325201ex23-1.htm EX-23.1 2653 3 CERTIFICATION ea028325201ex31-1.htm EX-31.1 9795 4 CERTIFICATION ea028325201ex31-2.htm EX-31.2 9788 5 CERTIFICATION ea028325201ex32-1.htm EX-32.1 3735 6 CERTIFICATION ea028325201ex32-2.htm EX-32.2 3631 7 GRAPHIC ea028325201_ex23-1img1.jpg GRAPHIC 18715 Complete submission text file 0001213900-26-038607.txt 7988224 Data Files Seq Description Document Type Size 8 XBRL SCHEMA FILE ispc-20251231.xsd EX-101.SCH 60559 9 XBRL CALCULATION FILE ispc-20251231_cal.xml EX-101.CAL 82817 10 XBRL DEFINITION FILE ispc-20251231_def.xml EX-101.DEF 312576 11 XBRL LABEL FILE ispc-20251231_lab.xml EX-101.LAB 629724 12 XBRL PRESENTATION FILE ispc-20251231_pre.xml EX-101.PRE 338234 82 EXTRACTED XBRL INSTANCE DOCUMENT ea0283252-10k_ispecimen_htm.xml XML 828580 Mailing Address 8 CABOT ROAD SUITE 1800 WOBURN MA 08101 Business Address 8 CABOT ROAD SUITE 1800 WOBURN MA 08101 781-301-6700 iSpecimen Inc. (Filer) CIK : 0001558569 (see all company filings) EIN. : 270480143 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 10-K | Act: 34 | File No.: 001-40501 | Film No.: 26829248 SIC : 8731 Services-Commercial Physical & Biological Research (CF Office: 08 Industrial Applications and Services)